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ABSTRACT
The poly(A) (pA) signal possesses a dual function in
3’ end processing of pre-mRNA and in transcrip-
tional termination of RNA polymerase II (Pol II) for
most eukaryotic protein-coding genes. A key pro-
tein factor in yeast and Drosophila Pol II transcrip-
tional termination is the 3’-end processing factor,
Pcf11. In vitro studies suggest that Pcf11 is capable
of promoting the dissociation of Pol II elongation
complexes from DNA. Moreover, several mutant
alleles of yeast Pcf11 effect termination in vivo.
However, functions of human Pcf11 (hPcf11) in Pol II
termination have not been explored. Here we show
that depletion of hPcf11 from HeLa cells reduces
termination efficiency. Furthermore, we provide
evidence that hPcf11 is required for the efficient
degradation of the 3’ product of pA site cleavage.
Finally, we show that these functions of hPcf11
require an intact pA signal.
INTRODUCTION
Most eukaryotic genes code for proteins and are trans-
cribed by RNA polymerase II (Pol II). Transcriptional
termination on these genes generally requires a poly(A)
(pA) signal, multiple trans-acting proteins and, in higher
eukaryotes, additional downstream sequences (1). Two
models have been proposed to explain the process: the
allosteric and torpedo hypotheses. The allosteric model
predicts that transcription of the pA signal induces a
change in the Pol II elongation complex that leads to
termination (2). The torpedo model postulates that a
50!30 exonuclease degrades the Pol II-associated product
of pA site cleavage and promotes termination upon
reaching the elongation complex (3,4). Accumulating
evidence suggests that Pol II termination incorporates
aspects of both of these models (5).
In humans and yeast, the 30 products of pre-mRNA
cleavage at the pA site are degraded by the 50!30
exonucleases, Xrn2 and Rat1, respectively, both of
which are required for eﬃcient Pol II termination (6–8).
In addition to cleavage at the pA site, some higher
eukaryotic pre-mRNAs are initially cleaved beyond the
pA signal (9,10). The best example of co-transcriptional
cleavage (CoTC) of pre-mRNA is in the human b-globin
gene (10). Degradation of the 30 product of CoTC, by
Xrn2, is also correlated with transcriptional termination
eﬃciency (11).
In addition to exonucleases, several proteins that play
roles in 30 end processing are also required for termination
(12). Of these, Pcf11 has emerged as a key factor in the
process. In yeast and Drosophila, Pcf11 is capable of
promoting the release of Pol II from DNA in vitro and
is also required for termination in vivo (12–15). Human
Pcf11 (hPcf11) is a component of cleavage factor II
(CFII), which is required for pre-mRNA cleavage during
30 end processing (16). More recent studies showed
that it facilitates premature termination at the HIV-1
promoter (17).
We have investigated the function of hPcf11 in Pol II
termination using RNA interference (RNAi) to deplete
it from HeLa cells. Depletion of hPcf11 in HeLa cells
reduces the eﬃciency of transcriptional termination on
transfected constructs and stabilizes the 30 products of
RNA cleavage at or beyond the pA site. Finally, we show
that these functions of hPcf11 require an intact pA signal.
MATERIALS AND METHODS
Oligonucleotides
Oligonucleotide sequences are provided in Table 1.
Constructs
pMAZ4 (8), pterm (previously called pCoTC) (11),
pCoTC (11), ppA (previously called pCoTCpA) (11),
Tat (18) and pRZ (previously called pHH) (11) have been
described. przMAZ4 was made by inserting the annealed
HHf/HHr primer pair into a vector prepared by Rzr/Rzf
PCR ampliﬁcation of pMAZ4. przMAZ4pA was made
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by ligation of a pAr/pAf PCR product obtained from
przMAZ4. The hPcf11 shRNA expression construct was
generated by inserting the annealed Pf/Pr primers into the
siSTRIKE vector (Promega). This vector is provided pre-
linearized.
Single-strandedM13 probes
The P and U3 (19), B3 and B4 (20) and A probes (11) have
been described previously. M is empty M13 vector.
Transfection
Sub-conﬂuent HeLa cells were transfected with 10 mg
of reporter plasmid and 1 mg of Tat, using 20 ml
of Lipofectamine 2000 (Invitrogen). RNA was isolated
12–24 h post-transfection.
RNA isolation
To isolate nuclear RNA, HeLa cell pellets were
re-suspended in 0.5ml of lysis buﬀer (10mM Tris–HCl,
140mM NaCl, 1.5mM MgCl2 and 0.5% NP-40). After a
5-min incubation on ice, the suspension was under layered
with 0.5ml of lysis buﬀer containing 24% (w/v) sucrose.
Tubes were spun at 13 000 r.p.m. in a bench-top centrifuge
for 10min. RNA was isolated from pelleted nuclei using
Trizol (Invitrogen), following the manufacturers instruc-
tions. When required, total RNA was also isolated using
Trizol. When analysing RZ cleavage by hsNRO, RNA
was also isolated under denaturing conditions, using
Trizol, in the absence of any divalent cations. This was
to prevent in vitro RZ cleavage.
RT-PCR
Reverse transcription was performed using SuperScript III
(Invitrogen) following the manufacturers guidelines.
Extension temperatures were 378C for oligo-dT and
558C for all other primers. Real-time PCR analysis was
performed using 10 pmol of each oligonucleotide, 7.5ml of
SYBR green mix (Qiagen) and 1/20th of the cDNA from
reverse transcription. All of this was in a 15-ml ﬁnal
volume. For each sample, a control experiment was
performed in the absence of reverse transcriptase to test
for any DNA contamination. The value obtained for the
minus reverse transcriptase control was deducted from
that obtained in the presence of reverse transcriptase in
order to obtain the RNA speciﬁc signal.
RNA interference
On Day 1, HeLa cells were transfected with 10 mg
of plasmid expressing hPcf11-speciﬁc shRNA (described
above) or a scrambled siRNA oligonucleotide
(siCONTROL1 from dharmacon). On day 3, cells were
transfected with the appropriate b-globin reporter plas-
mid, the Tat expression plasmid and, where required, the
VA plasmid. Assays were performed on Day 4. hPcf11
and drosha mRNA were detected by PCR using primers
Pcf1150/Pcf1130 and Drosha50/Drosha30, respectively, fol-
lowing cDNA synthesis with oligo-dT.
Hybrid selection
The hybrid selection procedure is described elsewhere,
including the exon 3 biotinylated anti-sense probe that
was used (19).
Nuclear run on (NRO) analysis
NRO analysis was performed as described in Ref. (20).
S1 nuclease analysis (S1A)
The probe to detect b-globin mRNA was prepared by
digesting the relevant b-globin reporter plasmid with
EcoR1, whilst the VA probe was prepared by digesting the
VA plasmid with BamH1. The procedure for radiolabel-
ling each probe and the protocol for the assay is taken
from Ref. (21).
Western blotting
Western blotting was performed as described by Ref. (17).
Blots were probed with anti-Pcf11 polyclonal anti-sera
(1:500 dilution), which was a kind gift from David
Gilmour’s lab and anti-actin (1:2000 dilution), which is
from SIGMA. Proteins were detected using an ECL kit
(GE healthcare).
Quantitation
S1A and NRO experiments were quantitated using
Microsoft imagequant software. Error bars represent the
standard error obtained from a minimum of three repeats.
RESULTS
To investigate the functions of hPcf11 in vivo, we used
RNAi to deplete it from HeLa cells. Depletion levels were
measured using RT-PCR and western blotting to analyse
hPcf11 mRNA and protein, respectively (Figure 1A). As
compared to the mock-treated sample, hPcf11 mRNA was
Table 1. Oligonucleotide sequences
upA GGGATATTATGAAGGGCCTTGAC
Rzr GAACTAGCTCTTCATTTCTTTATG
Rzf CCTTGGGAAAATACACTATATC
Vf CAGGAAACTATTACTCAAAGGGTA
Vr TTGAATCCTTTTCTGAGGGATG
pAr AATCCAGATGCTCAAGGCC
HHr CCTGTCACCGGATGTGTTTTCCGGTCT
GATGAGTCCGTGAGGACGAAACAGG
HHr CCTGTTTCGTCCTCACGGACTCATCAG
ACCGGAAAACACATCCCGGTGACAGG
pAf CTGCCGAATTCAAAACATTTATTTTC
RT AAACCCGACAGGACTATAAAGATAC
RTf CAGGAAACTATTACTCAAAGGGTA
RTr AGAAAATACCGCATCAGGCGC
Pf ACCGCAGCAACAGCATCGATTATTCAA
GAGATAATCGATGCTGTTGCTGCTTTTTC
Pr TGCAGAAAAAGCAGCAACAGCATCGAT
TATCTCTTGAATAATCGATGCTGTTGCTG
Pcf1150 GAAGATCAAGATGTTCCAGATC
Pcf1130 GTTCTTCCAGATCAGCTATCTC
Drosha50 GAGACCTAGCCTAGTTTTCCTG
Drosha30 AATGCACATTCACCAAAGTCAAG
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reduced in the shRNA-treated sample (kd, panel 1). This
reduction varied between 2- and 3-fold between replicate
experiments, as determined by real-time RT-PCR (data
not shown). However, levels of drosha mRNA (panel 2),
which was used as a control, remained similar. hPcf11
protein was also depleted by the shRNA treatment
(panel 3). The multiple bands may correspond to diﬀerent
isoforms, previously seen by mass spectrometry (16). In
contrast, actin protein levels were unchanged (panel 4).
These data show that shRNA treatment causes speciﬁc
partial depletion hPcf11 from HeLa cells. We predict that
the essential nature of hPcf11 function may preclude more
eﬃcient depletion, since this would result in cell death.
Previous results show that hPcf11 is required for pA
site cleavage in vitro (16). To test this in vivo, mock- or
shRNA-treated HeLa cells were transfected with pMAZ4
and the VA co-transfection control plasmid. pMAZ4
contains the b-globin gene, with transcription driven by
the HIV promoter, followed by the MAZ4 termination
element (Figure 1B). Levels of b-globin mRNA were
determined using S1A with probes speciﬁc to the b-globin
and VA transcripts (Figure 1B). After normalizing to the
VA control signal, we observed that b-globin mRNA
levels were reduced to 40% of the mock levels (lane 1)
after depletion of hPcf11 (lane 2). These bands are speciﬁc
to b-globin since they are not present in the control lane,
which displays the probes and tRNA treated with S1
nuclease (lane 3). Lane 4 shows the undigested probes.
This experiment was also validated using real-time
RT-PCR to detect b-globin mRNA, which again revealed
a reduction (to 31%) of the value for mock-treated HeLa
cells (quantitation is shown underneath the S1A gel).
No above-background signals were observed that repre-
sent unprocessed pre-mRNA, presumably because of its
instability. Therefore, although this experiment strongly
suggests that full levels of hPcf11 are required for 30
processing in vivo, changes in transcription and/or mRNA
turnover rates may also be responsible.
To rule out eﬀects of hPcf11 on transcription and/or
pre-mRNA turnover, mock-treated or hPcf11-depleted
HeLa cells were transfected with pMAZ4 and the VA
plasmid and nuclear RNA was isolated. This was reverse
transcribed using the dpA primer and cDNA was real-
time PCR ampliﬁed with pAR and upA to detect b-globin
pre-mRNA, not cleaved at the pA site (Figure 1C). hPcf11
depletion resulted in a 3.5-fold increase in pre-mRNA
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Figure 1. hPcf11 depletion and its eﬀect on 30 end processing. (A) Analysis of the eﬃciency of hPcf11 RNAi treatment. Panel 1; hPcf11 mRNA in
mock cells or hPcf11-depleted cells (kd). Panel 2; drosha mRNA. Panel 3; hPcf11 protein. Panel 4; actin protein. (B) S1 analysis of b-globin mRNA
levels in mock- and hPcf11-depleted cells (kd). The diagram shows the pMAZ4 plasmid, depicting b-globin exons (white boxes), pA signal (pA),
MAZ4 termination element (hatched box) and S1 probe (shown above plasmid). Bands for the VA transfection control (VA) and b-globin mRNA
(bpA) are indicated with arrows. Undigested probe is indicated with an asterisk. Lanes 3 and 4 show the b-globin and VA probes in the presence
(P+) and absence (P–) of S1 nuclease, respectively. Note, that the P– lane only contains 20% of the probe used in the analysis to prevent it
appearing overexposed on the gel. Quantitation measures the percentage of b-globin mRNA in kd cells as compared to mock cells (value ﬁxed at
100%). Quantitation of a real-time RT-PCR experiment used to detect b-globin mRNA is also shown. (C) Real-time RT-PCR analysis of b-globin
pre-mRNA, not cleaved at the pA site, in mock-treated and hPcf11-depleted cells (kd). The diagram shows primers used for reverse transcription
(dpA) and for PCR (upA/pAr). Graph shows fold change in the abundance of this species. The value obtained in mock-treated cells is set to 1.
Nucleic Acids Research, 2008, Vol. 36, No. 3 907
levels as compared to mock treatment. The enhanced
pre-mRNA accumulation indicates that transcription is
not reduced by hPcf11 depletion nor is RNA turnover
enhanced (these defects would most likely reduce levels
of pre-mRNA). Moreover, the enhanced accumulation
of pre-mRNA is consistent with the reduction in mRNA
seen in Figure 1B. Taken together, results in Figure 1B
and C indicate that hPcf11 is required for eﬃcient 30 end
processing in vivo.
hPcf11 is required for efficient Pol II termination
We next examined the potential role of hPcf11 in Pol II
transcriptional termination by performing NRO. NRO
measures the position and abundance of elongating Pol II
via hybridization of de novo radiolabelled transcripts to
complementary probes that are immobilized to a ﬁlter. We
performed NRO on mock- and hPcf11-depleted HeLa
cells transfected with pMAZ4 (Figure 2A). As we have
previously observed, termination on pMAZ4 was eﬃcient
in mock-treated cells. This is shown by the low signals
over probes downstream of the MAZ4 termination
element (A and U3) compared to those upstream (P-B4).
Depletion of hPcf11 reduces the eﬃciency of transcrip-
tional termination on pMAZ4, causing a 2-fold increase
in signals over read-through probes A and U3.
Quantitation is shown in the accompanying graph.
In addition to the MAZ4 termination sequence, work
from our lab identiﬁed a sequence in the 30 ﬂank of the
human b-globin gene, called the CoTC element, as an
eﬃcient transcriptional terminator (10). The CoTC
element functions diﬀerently to the MAZ4 element, at
least in part because the transcripts produced from it are
co-transcriptionally cleaved. We were interested to deter-
mine how this alternative mode of termination was
aﬀected by hPcf11 depletion. NRO was performed on
mock- and hPcf11-depleted HeLa cells transfected with
pCoTC, which contains the CoTC element instead of the
MAZ4 sequence (Figure 2B). Eﬃcient termination was
observed in mock-treated cells, since signal levels over
read-through probes A and U3 are similar to those over
the background M probe. However, depletion of hPcf11
resulted in elevated A and U3 signals, showing that
eﬃcient termination over the CoTC sequence also requires
hPcf11. In contrast, very little change was observed over
probes P-B4 as expected. Quantitation of this experiment
is shown in the accompanying graph. Quantitation of a
control NRO carried out on a construct with a mutated
pA signal (ppA) is also shown. Since loss of pA signal
function also promotes loss of Pol II termination, hPcf11
depletion causes no further eﬀect.
Although NRO provides the best measure of termina-
tion eﬃciency, we sought to conﬁrm that hPcf11 is
required for termination using RT-PCR (Figure 2C).
Nuclear RNA was isolated from mock-treated and
hPcf11-depleted HeLa cells transfected with pCoTC or
pMAZ4. cDNA was made with either oligo-dT or primer
RT and then real-time PCR ampliﬁed with the pAr/upA
primer pair (to detect b-globin mRNA) or the RTf/RTr
primer pair (to detect read-through transcripts). Read-
through was calculated as a ratio of these two products.
For both the pMAZ4 and pCoTC, we observed 7-fold
more read-through RNA in the hPcf11-depleted cells than
in the mock-treated cells. This is an enhanced eﬀect when
compared to the above NRO, possibly due to the
accumulation of read-through product over time. It is
important to note that RT-PCR measures the steady-state
RNA levels that accumulate over time, whereas NRO
provides a ‘snap-shot’ of the consequences of shRNA
treatment. Based on both NRO and RT-PCR experi-
ments, we conclude that hPcf11 is required for eﬃcient
transcriptional termination on both pCoTC and pMAZ4.
hPcf11 is required todegrade the3’productof pAsite cleavage
Recent studies show that yeast Pcf11 and Rat1 co-recruit
each other to the 30 end of genes (6). This indicates that
they may cooperate in the transcriptional termination
process. We next investigated potential hPcf11 eﬀects on
the function of Xrn2 (the human homologue of Rat1) in
termination. We have shown that Xrn2 is required for
degradation of the 30 pA site cleavage product (8). We
therefore tested the eﬀect of hPcf11 on this degradation
process using the hybrid selection technique (19). In brief,
a biotinylated anti-sense RNA probe was hybridized to
b-globin exon 3 and the resulting hybrids were bound
to streptavidin-coated magnetic beads (Figure 3A). The
selected bound RNA fraction includes b-globin mRNA
and pre-mRNA not cleaved at the pA site. However, the 30
product of pA site cleavage remains unbound because it is
not continuous with exon 3. It should be noted that results
in Figure 1B show hPcf11 to be required for full 30-end
processing eﬃciency. Therefore, depletion of hPcf11
would be anticipated to yield less of the 30 product of
pA site cleavage. Thus, these experiments were equalized
to the signal obtained for b-globin mRNA (data not
shown), which was normalized against the VA
co-transfection control plasmid transcripts.
Although previous NRO experiments have shown that
hybrid selection is very eﬃcient (10), we performed a
control RT-PCR experiment to establish this for our
particular experiment. HeLa cells were transfected with
pMAZ4 and nuclear RNA was isolated. The RNA was
then reverse transcribed using primer dpA and the
resulting cDNA was PCR ampliﬁed using the upA/dpA
primer pair in order to detect RNA not cleaved at the pA
site. A strong band was observed that represents this
species (lane 1, Figure 3B). Next, an equivalent amount of
the isolated RNA was selected with the biotinylated probe
speciﬁc to exon 3. The unbound fraction of selected RNA
was then analysed by RT-PCR under the same conditions.
In this case, no band was detected (lane 2). The absence of
un-cleaved b-globin pre-mRNA in the unbound fraction
clearly shows that the hybrid selection technique is close to
100% eﬃcient.
Next, we used hybrid selection to isolate the 30 product
of b-globin pA site cleavage. Mock-treated and hPcf11-
depleted HeLa cells were transfected with pMAZ4 and the
VA control plasmid and the unbound fraction of hybrid
selected nuclear RNA was analysed using RT-PCR
(Figure 3C). To detect the 30 pA site cleavage product,
cDNA was made with the Vr primer and was then PCR
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ampliﬁed using Vr and Rzf primers. After normalizing to
the VA signal and levels of cleaved mRNA, we observed
over 3-fold more of this RNA in the hPcf11-depleted
sample as compared to the mock-treated sample. Data in
Figure 3B show that this signal does not result from
contaminating un-processed RNA, since this is eﬃciently
removed by hybrid selection. Moreover, even when hybrid
selection was not used to purify the 30 pA site cleavage
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product, we observed enhanced accumulation of RNA
beyond the pA site in hPcf11-depleted samples (data not
shown). Therefore, these data indicate that hPcf11 is in
some way required to degrade the 30 product of pA site
cleavage.
We next asked if the hPcf11-dependent degradation
occurred even where transcriptional termination was
ineﬃcient. To do this, we repeated the above experiment
on a construct (pterm) that contains the human b-globin
gene without any downstream termination elements.
The NRO in Figure 3D conﬁrms that termination is
very ineﬃcient on pterm, as shown by the high A and
U3 signals from read-through Pol II. To analyse the
stability of the 30 pA site cleavage product, pterm and
VA were transfected into mock-treated and hPcf11-
depleted HeLa cells and nuclear RNA was isolated and
hybrid selected as described above. The unbound fraction
of selected RNA was then used for RT-PCR analysis
(Figure 3D). cDNA was made using the Vr primer and
then PCR ampliﬁed using the Vr/Rzf primer pair. After
normalizing to the VA and b-globin mRNA signals, we
found 3.5-fold more of the Vr/Rzf product in the
hPcf11-depleted sample as compared to the mock sample.
This shows that degradation of the 30 pA site cleavage
product requires hPcf11, even in the absence of transcrip-
tional termination. This also demonstrates that hPcf11
and RNA degradation are not suﬃcient for termination.
These results therefore serve to highlight the complexity of
Pol II termination in humans and the role that speciﬁc
sequences, beyond the pA signal, play in the process.
The pA signal is required for hPcf11-dependent degradation
of RNA
We next investigated the potential role of the pA signal in
hPcf11-dependent RNA degradation. It should be noted
that a construct containing a mutated pA signal would not
provide this information since such a mutation abolishes
cleavage at the pA site and so no ‘exposed’ 50 RNA end
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would be presented to the degradation machinery. It was
therefore necessary to create a situation where a degrad-
able Pol II-associated RNA was produced in the absence
of a pA signal. To achieve this, we created a further two
constructs: przMAZ4, where a hammerhead ribozyme
(RZ) was positioned between the pA signal and MAZ4
sequence (see diagram in Figure 4A) and przMAZ4pA,
in which the pA signal of przMAZ4 was inactivated by
mutation. In each situation, RZ cleavage severs the RNA
independently of a pA signal, which results in an exposed
50 RNA end in the absence of pA site cleavage. We
previously noted that RZ cleavage was not suﬃcient to
promote transcriptional termination (11). However, some
recent experiments have shown that positioning the
MAZ4 element beyond the RZ promotes eﬃcient termi-
nation and that this was preceded by 50!30 degradation of
the Pol II-associated RZ cleavage product (West,S.,
Proudfoot,N.J. and Dye,M.J. submitted for publication).
These same studies revealed that termination on
przMAZ4 is just as eﬃcient as on pMAZ4 and that a
construct containing a RZ-inactivating point mutation
also behaves like pMAZ4.
We previously showed that this RZ cleaves co-tran-
scriptionally in vivo (11). However, we needed to establish
whether RZ cleavage was faster than b-globin pA site
cleavage to know which cleavage event generated the
initial Pol II-associated RNA on przMAZ4. To do this, we
inserted the RZ beyond the b-globin pA signal, in pterm,
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shows selected transcripts (bound) and the bottom panel shows unselected transcripts (un-bound). NRO probes are shown in the diagram. (C) Real-
time RT-PCR analysis of transcriptional termination on przMAZ4 or przMAZ4pA in mock-treated or hPcf11-depleted (kd) cells. The plasmid is
przMAZ4, where the RZ is shown by a white circle. The primers used for reverse transcription (RT) and PCR (RTf/RTr) are shown. The top
diagram depicts the 30 end of the mRNA (from the ﬁnal exon to the poly(A) tail). Primers used for reverse transcription (oligo-dT) and PCR (upA/
pAr) are indicated. Read-through was calculated as a ratio of the two PCR products and set at 1 in mock-treated cells. (D) Real-time RT-PCR
analysis of the 30 RZ cleavage product in mock-treated and hPcf11-depleted (kd) cells. Primers used for cDNA synthesis (Vr) and subsequent PCR
(Rzf/Vr) are shown in the diagram. The RZ is again depicted by a white circle. Graph shows fold change where the value for mock-treated cells is
given a value of 1.
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to form pRZ. HeLa cells were transfected with pRZ and
hybrid selection NRO (hsNRO) was performed. For
hsNRO, radiolabelled nascent transcripts are selected
with biotinylated probes (in the same way described in
Figure 3). Both the selected RNA and the RNA that
escaped selection were retained and hybridized to separate
ﬁlters containing anti-sense M13 probes. It is important to
note that the possibility of in vitro RZ cleavage during this
experiment was minimized (see Materials and Methods
section). The top panel in Figure 4B shows the proﬁle of
nascent pRZ RNA that was selected with the biotinylated
probe. Strikingly, the only above-background signals
(higher than probe M) in the selected fraction were over
regions B3 and B4, which cover the region spanned by the
selection probe and the downstream region, between the
pA signal and RZ. Strikingly, transcripts beyond the RZ
(that would hybridize to probes A and U3) are present
exclusively in the unselected RNA (lower panel,
Figure 4B). The absence of B3 signal in this fraction
illustrates that selection of this RNA was close to 100%
eﬃcient. Furthermore, the absence of B4 signal in the
unselected fraction demonstrates that cleavage at the pA
site has not occurred. This result shows that transcripts
continuous with exon 3 extend up to the RZ but not into
region A, which lies only 350-bp downstream. Previous
data from our lab showed that cleavage of the b-globin pA
site does not take place until Pol II has transcribed at least
850 bp (19). Therefore, RZ cleavage is faster than b-globin
pA site cleavage. These data show that on przMAZ4, the
initial Pol II-associated RNA is produced by RZ cleavage.
We compared transcriptional termination eﬃciency on
przMAZ4, in both mock- and hPcf11-depleted cells, using
the RT-PCR assay described in Figure 2C (Figure 4C).
cDNA was made with either oligo-dT or primer RT and
then PCR ampliﬁed using the pAr/upA or the RTf/RTr
primer pairs to detect b-globin mRNA or read-through
RNA, respectively. There was 8-fold more read-through
RNA in the hPcf11-depleted cells than in the mock-treated
cells. This shows that hPcf11 is required for eﬃcient
termination on this construct. We next performed the
same assay on mock- and hPcf11-depleted cells transfected
with przMAZ4pA. Mutation of the pA signal inhibits
Pol II termination (1) and so high levels of read-through
RNA are produced, even in mock-treated cells. Con-
sequently, hPcf11 depletion had very little eﬀect on the
level of read-through RNA produced from this construct,
which is in agreement with data on ppA, which is
presented in Figure 2B. Although these data were pre-
dicted, given the anticipated role of hPcf11 in termination
of Pol II, they further support conclusions drawn from
experiments presented in Figures 1–3.
We next examined the eﬀect of hPcf11 depletion on the
stability of the 30 RZ cleavage product to see if the reduced
termination eﬃciency on przMAZ4 was correlated with
enhanced stability of this species. Mock- and hPcf11-
depleted HeLa cells were transfected with przMAZ4
together with the VA plasmid and nuclear RNA was
isolated for RT-PCR analysis (Figure 4D). cDNA was
made using the Vr primer and then PCR ampliﬁed with
the Vr/Rzf primer pair in order to detect the 30 RZ
cleavage product. After normalizing to the VA signal, we
observed 4-fold more of this species in hPcf11-depleted
cells than in mock-treated cells. This indicates that the 30
RZ product is a substrate for hPcf11-dependent degrada-
tion just as the 30pA site cleavage product is. We ﬁnally
repeated the experiment on przMAZ4pA. In this case,
hPcf11 depletion did not change the amount of 30 RZ
cleavage product. This is in spite of RZ cleavage creating a
degradable substrate. Consequently, these results indicate
that hPcf11-dependent degradation of cleaved RNA is
completely coupled to transcription of a pA signal. This
result further highlights the interconnections between
30 end processing and transcriptional termination.
DISCUSSION
50!30 degradation of Pol II-associated RNA, following
transcript cleavage, has been shown to be required for
termination on the protein-coding genes so far tested
(6,7,11,22). How this leads to Pol II release is unclear.
Since digestion of Pol II-associated RNA in vitro does not
cause disassembly of the ternary complex (23), other
factors may be required. Recent studies on yeast and
Drosophila Pcf11 show that it has the capability to dis-
mantle the ternary complex in vitro (13,15). Moreover, it
may aid recruitment of the Rat1 exonuclease to the 30 end
of genes in vivo (6). These observations have lead to a view
that Rat1 and Pcf11 may cooperate to promote transcrip-
tional termination as part of a mechanism that incorpo-
rates aspects of both the torpedo and allosteric models.
It was recently shown that hPcf11 aﬀects transcription
from the HIV promoter in the absence of other activating
factors (17). This leads to the conclusion that hPcf11 may
normally repress HIV gene expression in the absence of
such factors. It is important to note that the constructs
that we use rely on the HIV promoter for transcription.
However, we do not anticipate that this inﬂuences our
conclusions, since our experiments are performed in the
presence of the trans-activating factor, Tat, which
promotes high levels of transcription.
In vitro, Pcf11 releases stalled or paused Pol II much
more eﬃciently than the processive elongating form
(13,15). It is interesting that the MAZ4 element was
originally identiﬁed as a Pol II pause element (24) and
could therefore fulﬁl a role of slowing down the post-pA
signal polymerase suﬃciently for it to become susceptible
to hPcf11. This may be why termination is ineﬃcient on
pterm, despite hPcf11 playing a role in degrading the 30
pA site cleavage product. It is not known if the CoTC
element functions to pause Pol II or whether cleavage of
its transcripts is the key to its function in termination.
Interestingly, Pol II can be stalled in vitro by digesting its
nascent RNA to within 50 nt of the active site (25). This
eﬀect may be mimicked in vivo by rapid transcript
cleavage, such as that promoted by CoTC.
The necessity of hPcf11 for RNA degradation could be
conveniently explained by invoking a complex containing
Xrn2 and hPcf11, which is recruited to Pol II after
transcription of the pA signal (Figure 5, Model 1).
Cleavage at the pA site (or at CoTC sites, in the case of
pCoTC) would precede degradation of Pol II-associated
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RNA by Xrn2, assisted by hPcf11. However, it is notable
that depletion of Rat1 or Xrn2 does not eﬀect cleavage at
the pA site (7,11,22), even though it has been claimed that
Rat1 is required for the eﬃcient recruitment of Pcf11 and
other factors to genes, which are themselves required for 30
end processing (6). It is therefore also possible that Xrn2
and hPcf11 are not recruited to genes in a 1:1 ratio
(Figure 5, Model 2). In vitro, Pcf11 binds more avidly to
Pol II CTD that is phosphorylated on serine 2 than to un-
phosphorylated CTD or CTD phosphorylated on serine
5 (26,27). However, deletion of the gene encoding the
protein responsible for serine 2 phosphorylation in yeast
(CTK1) does not eﬀect either the recruitment of Rat1 to
genes nor transcriptional termination (7). Therefore, Xrn2
may recruit further hPcf11 to the cleaved transcript in
addition to the hPcf11 involved in 30 end processing.
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